1-8 of 8
Valter Torri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4548: The association between tissue genomic alterations and ctDNA shedding in non small cell lung cancer

Free
Robert Cameron, Anna Di Lello, Faith Abodunrin, Sulin Wu, Alessandra Esposito, Apameh Pezeshk, Valter Torri, Christine Bestvina, Marina Garassino
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 4548.
https://doi.org/10.1158/1538-7445.AM2025-4548
Published: 21 April 2025
View articletitled, Abstract 4548: The association between tissue genomic alterations and ctDNA shedding in non small cell lung cancer
Journal Articles

Abstract 2014: Immune exclusion signatures identify patients at high risk of relapse despite adjuvant chemotherapy in stage 2 colon cancer in the TOSCA phase 3 trial: PROSIT study

Free
Luca Mazzarella, Alberto Puccini, Lorenzo Ferrando, Gianmaria Frige', Eliana Rulli, Anna Maria Pessino, Alessandro Pastorino, Valentino Martelli, Anna Garuti, Davide Bedognetti, Alberto Ballestrero, Valter Torri, Roberto Labianca, Matteo Fassan, Sara Lonardi, Gabriele Zoppoli, Alberto Sobrero
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 2014.
https://doi.org/10.1158/1538-7445.AM2025-2014
Published: 21 April 2025
View articletitled, Abstract 2014: Immune exclusion signatures identify patients at high risk of relapse despite adjuvant chemotherapy in stage 2 colon cancer in the TOSCA phase 3 trial: PROSIT study
Journal Articles

Abstract 3638: Pathologic endpoints as surrogates for survival endpoints in neoadjuvant immunotherapy clinical trials for non-small cell lung cancer

Free
Robert B. Cameron, Jacobi B. Hines, Alessandra Esposito, Christine Bestvina, Marina C. Garassino, Valter Torri, Rajat Thawani
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3638.
https://doi.org/10.1158/1538-7445.AM2024-3638
Published: 22 March 2024
View articletitled, Abstract 3638: Pathologic endpoints as surrogates for survival endpoints in neoadjuvant immunotherapy clinical trials for non-small cell lung cancer
Journal Articles

Abstract CT261: METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer

Free
Paolo Luraghi, Luca Lazzari, Maria Vittoria Dieci, Serena Bellani, Chiara Soffientini, Rosario Rizzuto, Antonio Rosato, Vincenzo Costanzo, Giorgio Scita, Giannino Del Sal, Massimiliano Pagani, Marco Foiani, Claudio Tripodo, Silvio Bicciato, Giovanni Blandino, Alberto Zambelli, Valter Torri, Matteo Fassan, PierFranco Conte, Silvia Marsoni, Stefano Piccolo
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT261.
https://doi.org/10.1158/1538-7445.AM2020-CT261
Published: 15 August 2020
View articletitled, Abstract CT261: METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer
Journal Articles

Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial

Free
Elena Elez, Filippo Pietrantonio, Andrea Sartore-Bianchi, Clara Montagut, Andres Cervantes, Stefania Sciallero, Maria Giulia Zampino, Stefania Mosconi, Valter Torri, Noelia Tarazona, Luca Lazzari, Paolo Luraghi, Susana Muñoz, Matteo Fassan, Enzo Medico, Livio Trusolino, Maria Rescigno, Salvatore Siena, Alberto Sobrero, Roberto Labianca, Josep Tabernero, Alberto Bardelli, Sara Lonardi, Silvia Marsoni
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT263.
https://doi.org/10.1158/1538-7445.AM2020-CT263
Published: 15 August 2020
View articletitled, Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial
Journal Articles

Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity

Free
Marina Chiara Garassino, Valter Torri, Mario Paolo Colombo, Antonio Sica
Journal: Cancer Research
Cancer Res (2018) 78 (20): 5729–5730.
https://doi.org/10.1158/0008-5472.CAN-18-2245
Published: 15 October 2018
View articletitled, Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity
Open the PDF for Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity in another window
Journal Articles

Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies

Free
Maria Silvia Cona, Valter Torri, Massimo Di Nicola, Marina Garassino, Michele Del Vecchio, Sara Cresta, Diego Signorelli, Silvia Damian, Matteo Duca, Alice Indini, Monica Niger, Filippo de Braud
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3943.
https://doi.org/10.1158/1538-7445.AM2016-3943
Published: 15 July 2016
View articletitled, Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies
Journal Articles

Abstract 2672: Early evaluation of response to Vemurafenib treatment with FDG PET/CT in patients with metastatic melanoma.

Free
Luigi Aloj, Corradina Caracò, Francesca Di Gennaro, Antonio M. Grimaldi, Ester Simeone, Marcello Curvietto, Corrado Caracò, Nicola Mozzillo, Valter Torri, Paolo A. Ascierto, Secondo Lastoria
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2672.
https://doi.org/10.1158/1538-7445.AM2013-2672
Published: 15 April 2013
View articletitled, Abstract 2672: Early evaluation of response to Vemurafenib treatment with FDG PET/CT in patients with metastatic melanoma.